COL18A1 and non-small cell lung carcinoma: (33) showed that 34 patients with advanced NSCLC received nivolumab plus rh-endostatin, ORR was 41.2% (14/34, 95% CI 23.7%-58.6%), DCR was 64.7% (22/34, 95% CI 47.8%-81.6%), mPFS was 6.8 months (95% CI 1.1-12.1), the mOS was 17.1 months (95% CI 6.6-27.6), and the one-year survival rate was 64.4% (95% CI 46.2-82.6%).